Industry to benefit from EU moves to cut red tape
This article was originally published in Scrip
Executive Summary
Six measures being taken to simplify the EU pharmaceutical legislation, including new rules on side-effect reporting and changes to marketing authorisations, could significantly reduce the administrative burden on companies and lead to savings of around €155 million, says the European Commission.